192 related articles for article (PubMed ID: 27525651)
21. Transcriptomics of the Vaccine Immune Response: Priming With Adjuvant Modulates Recall Innate Responses After Boosting.
Santoro F; Pettini E; Kazmin D; Ciabattini A; Fiorino F; Gilfillan GD; Evenroed IM; Andersen P; Pozzi G; Medaglini D
Front Immunol; 2018; 9():1248. PubMed ID: 29922291
[TBL] [Abstract][Full Text] [Related]
22. Immune responses induced by heterologous boosting of recombinant bacillus Calmette-Guerin with Ag85B-ESAT6 fusion protein in levamisole-based adjuvant.
You Q; Wu Y; Jiang D; Wu Y; Wang C; Wei W; Yu X; Zhang X; Kong W; Jiang C
Immunol Invest; 2012; 41(4):412-28. PubMed ID: 22360290
[TBL] [Abstract][Full Text] [Related]
23. An ESAT-6:CFP10 DNA vaccine administered in conjunction with Mycobacterium bovis BCG confers protection to cattle challenged with virulent M. bovis.
Maue AC; Waters WR; Palmer MV; Nonnecke BJ; Minion FC; Brown WC; Norimine J; Foote MR; Scherer CF; Estes DM
Vaccine; 2007 Jun; 25(24):4735-46. PubMed ID: 17499400
[TBL] [Abstract][Full Text] [Related]
24. Vaccination of cattle with a CpG oligodeoxynucleotide-formulated mycobacterial protein vaccine and Mycobacterium bovis BCG induces levels of protection against bovine tuberculosis superior to those induced by vaccination with BCG alone.
Wedlock DN; Denis M; Skinner MA; Koach J; de Lisle GW; Vordermeier HM; Hewinson RG; van Drunen Littel-van den Hurk S; Babiuk LA; Hecker R; Buddle BM
Infect Immun; 2005 Jun; 73(6):3540-6. PubMed ID: 15908383
[TBL] [Abstract][Full Text] [Related]
25. AdHu5Ag85A Respiratory Mucosal Boost Immunization Enhances Protection against Pulmonary Tuberculosis in BCG-Primed Non-Human Primates.
Jeyanathan M; Shao Z; Yu X; Harkness R; Jiang R; Li J; Xing Z; Zhu T
PLoS One; 2015; 10(8):e0135009. PubMed ID: 26252520
[TBL] [Abstract][Full Text] [Related]
26. Protection against Mycobacterium tuberculosis challenge in mice by DNA vaccine Ag85A-ESAT-6-IL-21 priming and BCG boosting.
Dou J; Wang Y; Yu F; Yang H; Wang J; He X; Xu W; Chen J; Hu K
Int J Immunogenet; 2012 Apr; 39(2):183-90. PubMed ID: 22152009
[TBL] [Abstract][Full Text] [Related]
27. Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with Ag85B-ESAT-6 in the IC31 adjuvant.
Kamath AT; Rochat AF; Valenti MP; Agger EM; Lingnau K; Andersen P; Lambert PH; Siegrist CA
PLoS One; 2008; 3(11):e3683. PubMed ID: 18997860
[TBL] [Abstract][Full Text] [Related]
28. Repeated Aerosolized-Boosting with Gamma-Irradiated Mycobacterium bovis BCG Confers Improved Pulmonary Protection against the Hypervirulent Mycobacterium tuberculosis Strain HN878 in Mice.
Cha SB; Kim WS; Kim JS; Kim H; Kwon KW; Han SJ; Eum SY; Cho SN; Shin SJ
PLoS One; 2015; 10(10):e0141577. PubMed ID: 26509812
[TBL] [Abstract][Full Text] [Related]
29. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv.
Romano M; D'Souza S; Adnet PY; Laali R; Jurion F; Palfliet K; Huygen K
Vaccine; 2006 Apr; 24(16):3353-64. PubMed ID: 16488518
[TBL] [Abstract][Full Text] [Related]
30. Boosting BCG with proteins or rAd5 does not enhance protection against tuberculosis in rhesus macaques.
Darrah PA; DiFazio RM; Maiello P; Gideon HP; Myers AJ; Rodgers MA; Hackney JA; Lindenstrom T; Evans T; Scanga CA; Prikhodko V; Andersen P; Lin PL; Laddy D; Roederer M; Seder RA; Flynn JL
NPJ Vaccines; 2019; 4():21. PubMed ID: 31149352
[TBL] [Abstract][Full Text] [Related]
31. Mucosal boosting of H56:CAF01 immunization promotes lung-localized T cells and an accelerated pulmonary response to Mycobacterium tuberculosis infection without enhancing vaccine protection.
Woodworth JS; Christensen D; Cassidy JP; Agger EM; Mortensen R; Andersen P
Mucosal Immunol; 2019 May; 12(3):816-826. PubMed ID: 30760832
[TBL] [Abstract][Full Text] [Related]
32. PPD induced in vitro interferon gamma production is not a reliable correlate of protection against Mycobacterium tuberculosis.
Elias D; Akuffo H; Britton S
Trans R Soc Trop Med Hyg; 2005 May; 99(5):363-8. PubMed ID: 15780343
[TBL] [Abstract][Full Text] [Related]
33. Enhanced effect of BCG vaccine against pulmonary Mycobacterium tuberculosis infection in mice with lung Th17 response to mycobacterial heparin-binding hemagglutinin adhesin antigen.
Fukui M; Shinjo K; Umemura M; Shigeno S; Harakuni T; Arakawa T; Matsuzaki G
Microbiol Immunol; 2015 Dec; 59(12):735-43. PubMed ID: 26577130
[TBL] [Abstract][Full Text] [Related]
34. Whole blood RNA signatures in tuberculosis patients receiving H56:IC31 vaccine as adjunctive therapy.
Alonso-Rodríguez N; Vianello E; van Veen S; Jenum S; Tonby K; van Riessen R; Lai X; Mortensen R; Ottenhoff THM; Dyrhol-Riise AM
Front Immunol; 2024; 15():1350593. PubMed ID: 38433842
[TBL] [Abstract][Full Text] [Related]
35. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers.
van Dissel JT; Arend SM; Prins C; Bang P; Tingskov PN; Lingnau K; Nouta J; Klein MR; Rosenkrands I; Ottenhoff TH; Kromann I; Doherty TM; Andersen P
Vaccine; 2010 Apr; 28(20):3571-81. PubMed ID: 20226890
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity and protective efficacy conferred by a novel recombinant Mycobacterium bovis bacillus Calmette-Guérin strain expressing interleukin-12p70 of human cytokine and Ag85A of Mycobacterium tuberculosis fusion protein.
Deng YH; He HY; Zhang FJ
Scand J Immunol; 2013 Dec; 78(6):497-506. PubMed ID: 24283772
[TBL] [Abstract][Full Text] [Related]
37. Tuberculosis vaccine development at a divide.
Kaufmann SH
Curr Opin Pulm Med; 2014 May; 20(3):294-300. PubMed ID: 24626237
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice.
Li Q; Yu H; Zhang Y; Wang B; Jiang W; Da Z; Xian Q; Wang Y; Liu X; Zhu B
Scand J Immunol; 2011 Jun; 73(6):568-76. PubMed ID: 21323695
[TBL] [Abstract][Full Text] [Related]
39. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis.
Andersen CS; Dietrich J; Agger EM; Lycke NY; Lövgren K; Andersen P
Infect Immun; 2007 Jan; 75(1):408-16. PubMed ID: 17074845
[TBL] [Abstract][Full Text] [Related]
40. A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area.
Hussein J; Zewdie M; Yamuah L; Bedru A; Abebe M; Dagnew AF; Chanyalew M; Yohannes AG; Ahmed J; Engers H; Doherty TM; Bang P; Kromann I; Hoff ST; Aseffa A
Trials; 2018 Jan; 19(1):24. PubMed ID: 29321075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
